🇺🇸 FDA
Patent

US 10683362

Recombinant immunotoxin targeting mesothelin

granted A61KA61K39/00A61K39/001168

Quick answer

US patent 10683362 (Recombinant immunotoxin targeting mesothelin) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K39/00, A61K39/001168, A61K47/6829, A61K47/6851